First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis

BACKGROUND: EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including afatinib, dacomitinib, erlotinib, gefitinib, and osimertinib have proven efficacy in terms of progression-free survival (PFS) in patients with non-small-cell lung cancer (NSCLC) harboring EGFR mutations. However, an overall view for c...

Descripción completa

Detalles Bibliográficos
Autores principales: Holleman, Marscha S, van Tinteren, Harm, Groen, Harry JM, Al, Maiwenn J, Uyl-de Groot, Carin A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388947/
https://www.ncbi.nlm.nih.gov/pubmed/30863108
http://dx.doi.org/10.2147/OTT.S189438

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388947/
https://www.ncbi.nlm.nih.gov/pubmed/30863108
http://dx.doi.org/10.2147/OTT.S189438

Ejemplares similares